Hestia Insight Inc. Signs Letter of Intent With Major Asian-Pacific Health Care Products Distributor
NEW YORK, NY, May 10, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Hestia Insight Inc. (OTCQB:HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced that it has entered into a Letter of Intent with Prisma Biotech Corporation, Taipei, Taiwan, (“Prisma Biotech”), beginning the potential M&A transaction due diligence process.
Related news for (HSTA)
- Hestia Insight Inc. Subsidiary Enters Into Corporate Advisory Agreement With Aquiva Medical Inc.
- Hestia Insight Inc. Unveils Innovative Marketing Plan to Assist Emerging Companies
- Hestia Insight Inc. Announces Upcoming Launch of AI-Powered IR Website Platform to Assist Start-Ups, Small and Medium Sized Companies
- Hestia Insight Inc. Signs Letter of Intent With Leading Wound Care Company